In this overall, uncertain global environment, India seems better placed. Currently, we are out of the cross hairs from the tariff perspective but need to watch what happens in April, when reciprocal tariff policies are implemented.Read More
As Q4 2025 unfolds, Indian equity markets are recovering from earlier downturns. Historical patterns suggest a pre-earnings rally, slight correction during results, and potential post-earnings rebound. Experts believe that market recovery hinges on corporate earnings and external factors, predicting an optimistic outlook if earnings improve.Read More
Super Iron Foundry’s shares will debut on the BSE SME platform at a slight premium over the IPO price of Rs 108. The company raised Rs 68 crore, which will fund working capital and debt repayment. It exports to Europe and the Middle East and has a 72,000 MT annual production capacity in West Bengal, bolstered by advanced automation.Read More
Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last week’s approval for Eluxadoline tablets for IBS treatment. The stock shows a hold rating with an 18% target price upside. Despite recent approvals, the shares have declined 7% year-to-date.Read More
Gold prices continue to rise as investors treat gold as an investment. Central banks are accumulating gold. Geopolitical risks and inflation concerns drive demand. Analysts predict that gold may reach Rs 1 lakh per 10 grams in the long-term. They recommend a systematic investment approach for investors to benefit from corrections.Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.
